A team of scientists has found a way to eliminate a debilitating（使衰弱的） side effect associated with one of the main chemotherapy drugs used for treating colon cancer. The strategy used in their preclinical（临床前的） research—inhibiting an enzyme in bacteria of the digestive tract（消化道） —could allow patients to receive higher and more effective doses of the drug, known as CPT-11 or Irinotecan. The study, spearheaded（带头，做先锋） by scientists at the University of North Carolina at Chapel Hill and involving collaborators at Albert Einstein College of Medicine of Yeshiva University and North Carolina Central University in Durham, is described in the November 5 issue of Science.

While the chemotherapy agent CPT-11 has proven useful in attacking colorectal（结肠直肠的） tumors, it can also cause severe diarrhea（腹泻，痢疾） - limiting the dosage that patients can tolerate and curbing the drug's potential effectiveness. The primary cause of the diarrhea is believed to be beta glucuronidase（葡萄糖醛酸酶） , an enzyme found in bacteria that live in the gastrointestinal tract（胃肠道） . After the liver has rendered CPT-11 inert（惰性的，呆滞的） , the drug enters the intestine where it's reactivated by the beta glucuronidase of the gut bacteria. The revived CPT-11 irritates the intestine and causes severe diarrhea in up to 30 percent of patients who receive it.

To overcome this crippling side effect, the UNC researchers decided to look for compounds that would block the action of beta glucuronidase without eliminating the gut bacteria, which are important for human health.

"We need to retain our intestinal（肠道的） bacteria – they help us digest food, make critical vitamins and protect us from infection," said Matthew R. Redinbo, Ph.D., who led the UNC research team, and is professor and chair of the chemistry department in the UNC College of Arts and Sciences and a member of the UNC Lineberger Comprehensive Cancer Center. "This targeted approach stops the one bacterial protein thought to cause the drug's devastating side effect, but without damaging the beneficial microbes or the intestines."

Study co-author, Sridhar Mani, M.D., professor of medicine and of genetics at Einstein, said the severe diarrhea caused by CPT-11 can sharply limit the dosage that cancer patients can receive. "Our tests showed conclusively（最后地，决定性地） that the inhibitor identified by our UNC colleagues prevented diarrhea in mice that were also receiving CPT-11. We're hopeful that clinical trials will show that administering this inhibitor when patients start taking CPT-11 allows for improvement in the drug's anti-tumor effect in patients with cancer."